GENERAL UROLOGY - Review

Current Applications of Artificial Intelligence in Benign Prostatic Hyperplasia

Volume 48 · Issue 4 Publish Date: July 22, 2022
Full Text PDF
DOI
Milap Shah
Robotics and Urooncology, Max Hospital and Max Institute of Cancer Care, New Delhi, India
Bhaskar K Somani
iTRUE (International Training and Research in Uro-oncology and Endourology) Group, Manipal, Karnataka, India
Patrick Rice
Department of Urology, University Hospital Southampton NHS Trust, Southampton, UK
Piotr Chlosta
Department of Urology, Jagiellonian University in Krakow, Kraków, Poland
Bhavan Prasad Rai
iTRUE (International Training and Research in Uro-oncology and Endourology) Group, Manipal, Karnataka, India
Sufyan Ibrahim
Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India
Rahul Paul
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
B.M. Zeeshan Hameed
Department of Urology, Father Muller Medical College, Karnataka, India
Nithesh Naik
iTRUE (International Training and Research in Uro-oncology and Endourology) Group, Manipal, Karnataka, India
Dasharathraj K Shetty
Department of Humanities and Management, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, India
Full Text Full Text PDF

Abstract

Artificial intelligence is used in predicting the clinical outcomes before minimally invasive treatments for benign prostatic hyperplasia, to address the insufficient reliability despite multiple assessment parameters, such as flow rates and symptom scores. Various models of artificial intelligence and its contemporary applications in benign prostatic hyperplasia are reviewed and discussed. A search strategy adapted to identify and review the literature on the application of artificial intelligence with a dedicated search string with the following keywords: “Machine Learning,” “Artificial Intelligence,” AND “Benign Prostate Enlargement” OR “BPH” OR “Benign Prostatic Hyperplasia” was included and categorized. Review articles, editorial comments, and non-urologic studies were excluded. In the present review, 1600 patients were included from 4 studies that used different classifiers such as fuzzy systems, computer-based vision systems, and clinical data mining to study the applications of artificial intelligence in diagnoses and severity prediction and determine clinical factors responsible for treatment response in benign prostatic hyperplasia. The accuracy to correctly diagnose benign prostatic hyperplasia by Fuzzy systems was 90%, while that of computer-based vision system was 96.3%. Data mining achieved sensitivity and specificity of 70% and 50%, respectively, in correctly predicting the clinical response to medical treatment in benign prostatic hyperplasia. Artificial intelligence is gaining attraction in urology, with the potential to improve diagnostics and patient care. The results of artificial intelligence-based applications in benign prostatic hyperplasia are promising but lack generalizability of results. However, in the future, we will see a shift in the clinical paradigm as artificial intelligence applications will find their place in the guidelines and revolutionize the decision-making process.

Cite this article as: Shah M, Naik N, Hameed BMZ, et al. Current applications of artificial intelligence in benign prostatic hyperplasia. Turk J Urol. 2022;48(4):262-267.

Similar Articles

Article Info
Published In
Journal Urology Research & Practice
Volume / Issue Volume 48 · Issue 4
Pages 262-267
History
Published Online July 22, 2022
Copyright
Affiliations
Milap Shah
Robotics and Urooncology, Max Hospital and Max Institute of Cancer Care, New Delhi, India
Bhaskar K Somani
iTRUE (International Training and Research in Uro-oncology and Endourology) Group, Manipal, Karnataka, India
Patrick Rice
Department of Urology, University Hospital Southampton NHS Trust, Southampton, UK
Piotr Chlosta
Department of Urology, Jagiellonian University in Krakow, Kraków, Poland
Bhavan Prasad Rai
iTRUE (International Training and Research in Uro-oncology and Endourology) Group, Manipal, Karnataka, India
Sufyan Ibrahim
Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India
Rahul Paul
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
B.M. Zeeshan Hameed
Department of Urology, Father Muller Medical College, Karnataka, India
Nithesh Naik
iTRUE (International Training and Research in Uro-oncology and Endourology) Group, Manipal, Karnataka, India
Dasharathraj K Shetty
Department of Humanities and Management, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, India
Cite this Article
Outlines